Posted on 5/24/2011 by Mr. Christopher Florentz of CSL Behring
CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX:CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented at the NORD Partners in Progress Celebration 2011 for “new treatments brought to market for patients with rare diseases.”
CSL Behring’s new treatment, factor XIII concentrate (human), is approved for the routine prophylactic treatment of congenital factor XIII deficiency, an extremely rare and potentially life-threatening bleeding disorder. Congenital factor XIII deficiency is estimated to affect one person in two million, with an incidence in the U.S. of approximately 150 people.
Posted on 3/29/2011 by Mr. Christopher Florentz of CSL Behring
CSL Limited (ASX:CSL) Australia’s leading biopharmaceutical company, has announced a change to its senior executive group. Peter Turner, President of CSL Behring in King of Prussia, PA, will hand over his responsibilities as President to Paul Perreault effective July 1, 2011.
Paul Perreault is currently a member of the CSL Behring leadership team holding the position Executive Vice President, Commercial Operations. His career spans 30 years in the pharmaceutical industry in sales, marketing, business development and operational roles with both a US and international focus.
The announcement can be viewed in its entirety at http://www.csl.com.au/s1/cs/auhq/1182280826145/news/1255926123898/prdetail.htm
CSL Behring's Key Issues Dialogue Series Examines Challenges in Treating Patients with Hereditary Angioedema
Posted on 9/22/2010 by Mr. Christopher Florentz of CSL Behring
CSL Behring announces publication of the latest in its ongoing Key Issues Dialogue Series – "Hereditary Angioedema (HAE) in the US." The Dialogue brought together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with HAE.
The participants included prominent physician-researchers who agreed that a lack of understanding about HAE is commonplace in the medical community, often resulting in unnecessary surgery and inappropriate treatment. The complete Dialogue is available for download: http://www.cslbehring-us.com/about-CSL-Behring/dialogue-series.htm
CSL Behring is a leader in the plasma protein therapeutics industry. The company manufactures and markets a range of plasma-derived and recombinant therapies worldwide for the treatment of rare and serious diseases and for use in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic diseases in the newborn.
CSL Behring Will Supply Plasma-Based Protein to ProFibrix
Posted on 6/21/2010 by Mr. Christopher Florentz of CSL Behring
CSL Behring in King of Prussia, PA - www.cslbehring.com - has entered into an agreement with ProFibrix B.V., which is headquartered in Leiden, the Netherlands and has a subsidiary in Seattle, to supply plasma-based fibrinogen and thrombin, which are blood-clotting proteins. ProFibrix will use the proteins, which CSL Behring extracts from blood plasma, to make an innovative topical tissue sealant for use during and after surgery to stop bleeding.
CSL Behring is a leader in the plasma protein therapeutics industry. The company develops and manufactures plasma-derived and recombinant therapies for people with rare and serious diseases.
